The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines (Q39846753)

15 September 2017

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines (English)

1 reference

ORCID Public Data File 2021

15 September 2017

1 reference

author name string

Brigette B Y Ma

1

1 reference

15 September 2017

Vivian W Y Lui

2

1 reference

15 September 2017

Edwin P Hui

3

1 reference

15 September 2017

Cecilia P Y Lau

4

1 reference

15 September 2017

Kakiu Ho

5

1 reference

15 September 2017

Margaret H L Ng

6

1 reference

15 September 2017

S H Cheng

7

1 reference

15 September 2017

Sai-Wah Tsao

8

1 reference

15 September 2017

Anthony T C Chan

9

1 reference

15 September 2017

27 May 2009

1 reference

Investigational New Drugs

15 September 2017

1 reference

15 September 2017

28

1 reference

15 September 2017

4

1 reference

15 September 2017

413-420

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-009-9269-x

15 September 2017

0 references

cites work

Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-009-9269-X

Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma.

21 January 2018

1 reference

12 December 2020

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

12 December 2020

Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma

1 reference

12 December 2020

Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells

1 reference

12 December 2020

AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway

1 reference

12 December 2020

Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells

1 reference

12 December 2020

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

1 reference

12 December 2020

Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins

1 reference

12 December 2020

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

1 reference

12 December 2020

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

1 reference

12 December 2020

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: current and future directions.

1 reference

12 December 2020

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

12 December 2020

Differential signaling pathways are activated in the Epstein-Barr virus-associated malignancies nasopharyngeal carcinoma and Hodgkin lymphoma

1 reference

12 December 2020

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

1 reference

12 December 2020

Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer.

1 reference

12 December 2020

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

1 reference

12 December 2020

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

1 reference

12 December 2020

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

1 reference

12 December 2020

10.1007/S10637-009-9269-X

Identifiers

DOI

1 reference

15 September 2017

1 reference